 Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies mAbs to treat life-threatening bacterial infections, today announced the appointment of Michael A. Nazak as its Chief Financial Officer CFO effective January 1, 2020. Mr. Nazak, who joined Aridis in November 2018, has been serving as Vice President, Finance and replaces Fred Kurland who has chosen to retire but will continue to support the Company as a consultant. 